MedTrace Logo

Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care

NCT04111809 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2025-09-25

No results posted yet for this study

Summary

The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in serum and urine until 12 months in Patients with Multiple Myeloma Treated With intravenous bisphosphonates in routine care.

Conditions

Interventions

BIOLOGICAL

Blood and urine collection

collected 10 mL of blood and 15 mL of urine every 2 months until 12 months

Sponsors & Collaborators

  • Intergroupe Francophone du Myelome

    collaborator NETWORK

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
65 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2020-10-20
Completion
2020-10-20

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04111809 on ClinicalTrials.gov